在IL-4Rα这一靶点上,战事正变得愈发焦灼。2月27日,赛诺菲再度加码——其明星产品度普利尤单抗注射液(Dupixent,达必妥?)在国内获批两项新适应症,分别用于治疗大疱性类天疱疮成人患者,以及6岁及以上儿童哮喘的维持治疗。几乎是同一时间,国产IL-4Rα单抗也掀起了新一轮“强攻”。CDE官网显示,2月底,两款IL-4Rα单抗—— 康方生物 的曼多奇单抗与 三生国健 的SSGJ-611——先后...
Source Link在IL-4Rα这一靶点上,战事正变得愈发焦灼。2月27日,赛诺菲再度加码——其明星产品度普利尤单抗注射液(Dupixent,达必妥?)在国内获批两项新适应症,分别用于治疗大疱性类天疱疮成人患者,以及6岁及以上儿童哮喘的维持治疗。几乎是同一时间,国产IL-4Rα单抗也掀起了新一轮“强攻”。CDE官网显示,2月底,两款IL-4Rα单抗—— 康方生物 的曼多奇单抗与 三生国健 的SSGJ-611——先后...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.